Wells Fargo’s OptimizeRx OPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$115K Sell
18,276
-10,627
-37% -$98.7K ﹤0.01% 5030
2025
Q4
$354K Buy
28,903
+7,576
+36% +$124K ﹤0.01% 4719
2025
Q3
$437K Sell
21,327
-3,203
-13% -$50.8K ﹤0.01% 4398
2025
Q2
$331K Buy
24,530
+4,411
+22% +$48.3K ﹤0.01% 4432
2025
Q1
$174K Buy
20,119
+8,911
+80% +$54.5K ﹤0.01% 4800
2024
Q4
$54.5K Buy
11,208
+2,797
+33% +$15.6K ﹤0.01% 5455
2024
Q3
$64.9K Sell
8,411
-213
-2% -$1.89K ﹤0.01% 5251
2024
Q2
$86.2K Buy
8,624
+837
+11% +$9.19K ﹤0.01% 5017
2024
Q1
$94.6K Buy
7,787
+583
+8% +$8.46K ﹤0.01% 4926
2023
Q4
$103K Buy
7,204
+873
+14% +$8.38K ﹤0.01% 4878
2023
Q3
$49.3K Sell
6,331
-3,615
-36% -$39.3K ﹤0.01% 5180
2023
Q2
$142K Buy
9,946
+3,714
+60% +$52.9K ﹤0.01% 4795
2023
Q1
$91.2K Buy
6,232
+988
+19% +$16.5K ﹤0.01% 4855
2022
Q4
$88.1K Sell
5,244
-1,417
-21% -$24.5K ﹤0.01% 4597
2022
Q3
$99K Buy
6,661
+1,919
+40% +$37.9K ﹤0.01% 4605
2022
Q2
$130K Sell
4,742
-22,168
-82% -$657K ﹤0.01% 4493
2022
Q1
$1.01M Sell
26,910
-10,248
-28% -$454K ﹤0.01% 3876
2021
Q4
$2.31M Buy
37,158
+5,742
+18% +$435K ﹤0.01% 3356
2021
Q3
$2.69M Sell
31,416
-7,821
-20% -$491K ﹤0.01% 3415
2021
Q2
$2.43M Sell
39,237
-1,300
-3% -$66.2K ﹤0.01% 3511
2021
Q1
$1.98M Buy
40,537
+9,276
+30% +$448K ﹤0.01% 3713
2020
Q4
$974K Sell
31,261
-2,065
-6% -$50.6K ﹤0.01% 4056
2020
Q3
$695K Sell
33,326
-4,917
-13% -$84.4K ﹤0.01% 4116
2020
Q2
$498K Buy
38,243
+5,177
+16% +$56.3K ﹤0.01% 4325
2020
Q1
$299K Buy
33,066
+7,934
+32% +$75.3K ﹤0.01% 4414
2019
Q4
$258K Buy
25,132
+2,714
+12% +$30.8K ﹤0.01% 4808
2019
Q3
$323K Buy
22,418
+8,856
+65% +$137K ﹤0.01% 4674
2019
Q2
$219K Buy
13,562
+1,180
+10% +$15.9K ﹤0.01% 4928
2019
Q1
$157K Buy
12,382
+1,898
+18% +$24.7K ﹤0.01% 4938
2018
Q4
$115K Buy
10,484
+7,484
+249% +$111K ﹤0.01% 5219
2018
Q3
$54K Buy
+3,000
New +$37.8K ﹤0.01% 5571

Other funds holding OPRX

Wells Fargo's OPRX Position: Q1 2026 in Review

Wells Fargo reduced its OptimizeRx (OPRX) stake by 37% in Q1 2026, selling an estimated $98.7K and leaving 18,276 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #5030.

Wells Fargo first reported a position in OPRX in Q3 2018 and has held it in 31 quarters since. The position peaked at $2.69M in Q3 2021. 127 funds tracked by Wall St. Rank hold OPRX as of Q1 2026.

  • Wells Fargo held 18,276 shares of OptimizeRx worth $115K as of Q1 2026.
  • Wells Fargo sold 10,627 OptimizeRx shares in Q1 2026, an estimated $98.7K.
  • OptimizeRx made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5030 holding.
  • Wells Fargo first reported a position in OptimizeRx in Q3 2018 and has held it in 31 quarters since.
  • Wells Fargo's OptimizeRx position peaked at $2.69M in Q3 2021.
  • 127 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.